Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SUPERNUS PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for SUPERNUS PHARMACEUTICALS, INC.

SUPN

SUPERNUS PHARMACEUTICALS, INC.

About SUPERNUS PHARMACEUTICALS, INC.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company specializing in developing and commercializing treatments for central nervous system (CNS) disorders. Its portfolio includes products for ADHD, Parkinson's disease, epilepsy, migraine, and dystonia. The company leverages proprietary technologies and strategic licensing to create innovative, patient-friendly medications, focusing on improving efficacy, safety, and adherence. It markets primarily in the U.S. through direct sales and partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from SUPERNUS PHARMACEUTICALS, INC.

1
1
SUPERNUS PHARMACEUTICALS, INC. Supernus Pharmaceuticals Reports 39% Revenue Growth to $207.7 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
SUPERNUS PHARMACEUTICALS, INC. Supernus Pharmaceuticals Reports 2025 Financial Results and Acquisition of Sage Therapeutics

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
SUPERNUS PHARMACEUTICALS, INC. Supernus Pharmaceuticals Reports $192.1M Revenue in Q3 2025, Net Loss of $45.1M

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
SUPERNUS PHARMACEUTICALS, INC. Supernus Pharmaceuticals Reports $165.5M Revenue in Q2 2025, Acquires Sage Therapeutics

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
SUPERNUS PHARMACEUTICALS, INC. Supernus Pharmaceuticals Reports $149.8 Million Revenue in Q1 2025, Net Loss of $11.8 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
SUPERNUS PHARMACEUTICALS, INC. Supernus Pharmaceuticals Reports 14% Revenue Growth, Improved Profitability in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments